‘Verapamil’ Category

Verapamil for Mania in Bipolar Disorder

Verapamil for Mania in Bipolar Disorder Verapamil, a type of calcium channel blocker, has been studied for years before as a treatment for manic e...

 

Verapamil for Mania in Bipolar Disorder
Verapamil, a type of calcium channel blocker, has been studied for years before as a treatment for manic episodes in patients with bipolar disorder. That being said, the scientific data behind it is scarce and controversial, which means some studies have found a benefit …
Read more about About – News & amp; Topics code

Combining Bedaquiline and Verapamil reduces side effects, improved the

 

The combination of Bedaquiline and Verapamil reduces side effects, improved the
New research at the Center for Tuberculosis Research at Johns Hopkins University School of Medicine shows that lower doses of the toxic drug Bedaquiline – together with verapamil, a drug that is used to treat various heart & amp; given nbsp treatment, …
Read more at News-Medical.net

Latest news verapamil

 

Verapamil increases the anti-tuberculosis activity Bedaquiline
Researchers at Johns Hopkins University School of Medicine in Baltimore, Maryland, have shown that giving lower doses of the drug to mice along with the calcium channel blocker verapamil may result in the same antibacterial activity as the full …
Read more at The Pharmaceutical Journal

Company Shares of Alkermes plc (NASDAQ: ALKS) drops by -1.82%

 

Company Shares of Alkermes plc (NASDAQ: ALKS) drops by -1.82%
… One VIVITROL line on a commercial scale. The company manufactures AMPYRA / FAMPYRA, RAPAMUNE and other products in Athlone, Ireland facility. It manufactures Focalin XR, Ritalin LA, Avinza, verapamil and other products in the Gainesville, & amp; nbsp; …
Read more at Insider Trade reporting code

Analyst Price Target Update on Alkermes plc

 

Analyst Price Target Update on Alkermes plc
Alkermes plc (NASDAQ:ALKS) should head towards $ 67.13 per share according to 8 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $ 37 per share. The higher price estimate target is at $ 81 according to the Analysts.
Read more on Money Flow Index